Portolan Capital Management LLC Grows Stake in Cellebrite DI Ltd. (NASDAQ:CLBT)

Portolan Capital Management LLC grew its position in shares of Cellebrite DI Ltd. (NASDAQ:CLBT) by 19.9% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,224,020 shares of the company’s stock after purchasing an additional 203,068 shares during the period. Cellebrite DI makes up 1.5% of Portolan Capital Management LLC’s portfolio, making the stock its 15th biggest holding. Portolan Capital Management LLC owned about 0.59% of Cellebrite DI worth $20,612,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in CLBT. Point72 Asia Singapore Pte. Ltd. grew its position in Cellebrite DI by 59.6% in the second quarter. Point72 Asia Singapore Pte. Ltd. now owns 2,724 shares of the company’s stock worth $33,000 after acquiring an additional 1,017 shares in the last quarter. Advisors Asset Management Inc. grew its position in Cellebrite DI by 130.5% in the third quarter. Advisors Asset Management Inc. now owns 3,077 shares of the company’s stock worth $52,000 after acquiring an additional 1,742 shares in the last quarter. Public Employees Retirement Association of Colorado purchased a new position in Cellebrite DI in the second quarter worth $71,000. Pathway Financial Advisers LLC grew its position in Cellebrite DI by 1,583.8% in the third quarter. Pathway Financial Advisers LLC now owns 4,378 shares of the company’s stock worth $74,000 after acquiring an additional 4,118 shares in the last quarter. Finally, nVerses Capital LLC purchased a new position in Cellebrite DI in the second quarter worth $103,000. 45.88% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several analysts have issued reports on the stock. Deutsche Bank Aktiengesellschaft upped their price target on shares of Cellebrite DI from $15.00 to $18.00 and gave the company a “buy” rating in a research report on Friday, August 16th. Needham & Company LLC upped their price target on shares of Cellebrite DI from $17.00 to $21.00 and gave the company a “buy” rating in a research report on Thursday, November 7th. Bank of America upped their price target on shares of Cellebrite DI from $13.00 to $17.00 and gave the company a “buy” rating in a research report on Friday, August 16th. JPMorgan Chase & Co. upped their price target on shares of Cellebrite DI from $21.00 to $22.00 and gave the company an “overweight” rating in a research report on Thursday, November 7th. Finally, TD Cowen upped their price target on shares of Cellebrite DI from $20.00 to $23.00 and gave the company a “buy” rating in a research report on Monday, September 23rd. Eight analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $20.29.

Cellebrite DI Stock Up 0.2 %

Shares of NASDAQ:CLBT opened at $20.40 on Wednesday. The company has a 50-day moving average price of $18.35 and a 200-day moving average price of $15.31. Cellebrite DI Ltd. has a 12 month low of $7.91 and a 12 month high of $21.00.

Cellebrite DI (NASDAQ:CLBT) last issued its quarterly earnings data on Wednesday, November 6th. The company reported $0.14 EPS for the quarter, beating the consensus estimate of $0.09 by $0.05. The firm had revenue of $106.90 million during the quarter, compared to the consensus estimate of $102.06 million. Cellebrite DI had a negative net margin of 82.28% and a positive return on equity of 122.59%. The company’s quarterly revenue was up 27.0% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.09 earnings per share. Equities analysts expect that Cellebrite DI Ltd. will post 0.32 earnings per share for the current year.

About Cellebrite DI

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.